Select your language

Designing and running regulatory strategy

Designing and running regulatory strategy


Medium-sized Biotechnology company.

Client Challenge:

Our client was developing a first-in-class, Phase 3 ready anti-FGFR2b antibody for the treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ).

They required regulatory expertise to guide the strategy and preparation for a Type B EOP2 multidisciplinary FDA Meeting covering regulatory, CMC, clinical, and biomarker design elements of the planned Phase 3 study.

G&L Solution:

Here, we assembled a G&L multidisciplinary team, including Regulatory, Companion Diagnostics, and Clinical experts.

We worked with the client’s development team to author and submit the Type B EOP2 Meeting Request and Briefing Book.

We also guided discussions and provided strategic input into critical regulatory strategy and Phase 3 study design elements. Key design elements included stratification of enriched patient population overexpressing FGFR2b versus a broader FGFR2b-positive population, pre-screening biomarker strategy, safety monitoring plans and risk mitigation strategies.


As a result of G&L’s guidance and collaboration, the client developed a robust and commercially viable Phase 3 development and regulatory strategy, and they were well-prepared for the FDA Type B Meeting. FDA granted Breakthrough Therapy Designation, and the asset was acquired by a leading global biopharmaceutical company.

Start your journey with G&L

Discover what G&L can do for you today.

Related Case Studies

Find out more about the solutions we provide to meet the biggest challenges in global healthcare.

Ready to reach your potential?

Discover how G&L can help you do business better

Contact Us